News and features

Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.

If you’re a journalist and want to find out more, you can contact our media relations team.

ICR Logo
Unravelling the complexity of cancer

20/08/13

So… when do you think they’ll find a cure for cancer?
ICR Logo
Illuminating myeloma

19/08/13

Imagine you’re in a dark room trying to solve a puzzle, but your only source of light is a narrow slit that illuminates just a single piece at a time. That might give some idea what it’s like to look for signs that a cancer has recurred for patients with myeloma, a cancer of the bone marrow.
ICR Logo
Major study links ageing gene to blood cancer

18/08/13

ICR scientists find four new genetic variants linked to myeloma, including a gene called TERC, previously linked to the ageing process.
ICR Logo
Chemotherapy reduces testicular cancer relapse and side effects

16/08/13

Giving men with stage 2 testicular cancer a single dose of carboplatin alongside radiotherapy could improve treatment effectiveness and reduce the risk of long-term side-effects, an ICR study reports.
ICR Logo
ICR researchers in new international trial for neuroblastoma

13/08/13

New 'BEACON' trial led by ICR scientists aims to tackle treatment-resistant form of childhood cancer neuroblastoma.
ICR Logo
Experimental breast cancer drugs could treat lung cancer too

12/08/13

Scientists discover that experimental drugs first developed for breast and ovarian cancer could be used to treat the most common type of lung cancer.
ICR Logo
Trial compares new drug combinations for breast cancer

08/08/13

A combination of two hormone therapy drugs does not provide significant clinical benefit over single-drug treatments, according to a trial.
Power of Words by Antonio Litterio, Creative Commons Attribution-Share Alike 3.0
Science Writer of the Year 2013

04/08/13

The ICR’s annual Mel Greaves Science Writing Prize – named in honour of the ICR Professor of Cell Biology and popular science author Professor Mel Greaves – aims to encourage imaginative writing about science that is engaging and understandable not only for fellow scientists but also for the wider public.
ICR Logo
Luke Johnson, leading entrepreneur, takes the helm at the ICR

01/08/13

This week, Luke Johnson, one of the UK’s most successful entrepreneurs and former Chairman of Channel 4, joins the ICR as Chairman.
ICR Logo
Cancer Research Technology, The Institute of Cancer Research and Merck Serono sign licensing deal on molecules that block the WNT signalling pathway

31/07/13

The Institute of Cancer Research, London, Cancer Research Technology, and Merck Serono have signed a licensing deal today extending an alliance to discover and develop anticancer drugs that block the WNT signalling pathway.
ICR Logo
Men with incurable prostate cancer living twice as long as decade ago

30/07/13

Patients with advanced prostate cancer treated with the latest therapies are living twice as long as a decade ago, a new ICR analysis reveals.
ICR Logo
Video: Men with advanced prostate cancer are living longer

29/07/13

Patients with advanced prostate cancer treated with the latest therapies are living on average for more than twice as long as a decade ago. Study leader Professor Johann de Bono told us why:

Make a donation today

A monthly gift can help support our research over several years, so it has the maximum possible benefit for people with cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

With your generous support, we can continue making more discoveries, finding more cures, and saving more lives.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Our research centres & divisions

Through our close partnerships with The Royal Marsden and other key UK institutions, we're leading a wide breadth of cancer research across eight divisions and more than 25 research centres and strategic initiatives.